Belgian anti-trust regulators fined Novartis nearly $2.8 million for making misleading statements about a treatment for a serious eye disease, the latest instance in which the company was cited by a government for anticompetitive practices in connection with the medication.
The fine is only the latest act in a long-running drama over Lucentis, which is used to treat age-related macular degeneration, a common disease among the elderly that can lead to blindness. However, an older and cheaper cancer medication called Avastin is often repackaged by physicians to treat the eye disease, even though it is not approved for that use.
Click this link for the original source of this article.
Author: Ed Silverman
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.